AMENDMENTS TO THE SPECIFICATION

Please insert the following section heading on page 1, at line 2:

-- BACKGROUND OF THE INVENTION --

Please replace the section heading on page 1, at line 3, with the following replacement heading:

-- TECHNICAL 1) FIELD OF THE INVENTION --

Please replace the section heading on page 1, at line 13, with the following replacement heading:

-- BACKGROUND2) DESCRIPTION OF RELATED ART

Please replace paragraphs [0005] through [0007] with the following replacement paragraphs:

[0005] Baruah Nabin C., et al. Journal of Organic Chemistry, 44, 1831 – 1835 (1979) discloses a compound represented by general formula (IV):

$$OH_3$$
 OH_3 OH_3 OH_4 OH_5 OH_5 OH_5 OH_6 OH_7 OH_8 OH_8 OH_9 OH_9

(hereinafter referred to as "TD-2").

Baruah Nabin C., et al. Journal of Organic Chemistry, 44, 1831 - 1835 (1979) discloses a compound represented by general formula (V):

$$CH_3$$
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_2
 CH_3
 CH_3

(hereinafter referred to as "TD-8").

Antonia G. Gonzalez, et al, Journal of Natural Products, 57, 400 – 402 (1994) discloses(4S,5R)-4-hydroxy-4-[(1E,3R)-3-hydroxy-1-butenyl]-3,3,5-trimethyl 1-cyclohexanone).

[0006] On the other hand, Raghwendra Pal., et al. Journal of Phamaceutical Science, 65, 918 – 920 (1976) reports that Tagitinin A to F have been isolated from an extract of Tithonia diversifolia (Hemsl) A. Gray and that, among these compounds, only Tagitinin F had the effect of prolonging the life span of mice in which P388 mouse leukemia was intraperitoneally transplanted. Here Tagitinin A corresponds to TD-7, Tagitinin C corresponds to TD-2, Tagitinin D corresponds to TD-9, and Tagitinin E corresponds to TD-8. However, Tagitinin F does not correspond to TD-1 to 10 according to the invention of this application.

[0007] Raghwendra Pal, et al. Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 15B, 208-211 (1977) discloses a compound represented by general formula (VI):

(hereinafter referred to as "TD-11").

Isao Agata, et al. Yakugaku Zasshi, 101, 1067-1071 (1981) discloses a compound represented by general formula (VII):

(IIV)

(hereinafter referred to as "TD-12").

S. Shibata, et al. Yakugaku Zasshi, 80, 620-624 (1960) discloses a compound represented by general formula (VIII):

(hereinafter referred to as "TD-13").

Christa Zdero, et al. Phytochemistry, 26, 1999-2006 (1987) discloses a compound represented by general formula (IX):

(hereinafter referred to as "TD-14").

Please replace paragraph [0009] with the following replacement paragraph:

[0009] The present inventors have now found novel compounds having anticancer activity and that certain known compounds have anticancer activity against specific cancer cells. The present invention has been made based on such finding. Accordingly, an object of the present invention is to provide novel compounds and use of known compounds having anticancer activity against specific cancer in pharmaceutical preparations.

W0068787.1 Page 5

First aspect of invention

According to a first aspect of the present invention, there are provided novel compounds represented by the following general formulae:

a compound represented by general formula (I):

wherein R_1 represents hydroxyl and R_2 represents methoxy (hereinafter referred to as "TD-3"); a compound represented by general formula (II):

$$R_4$$
 CH_3
 C

wherein R_3 represented hydroxyl and R_4 represents methoxy (hereinafter referred to as "TD-6"); and

a compound represented by general formula (III):

(III)

wherein 3-hydroxyl in 3-hydroxy-1-butenyl is in a 3S configuration (hereinafter referred to as "TD-5").

Please replace the section heading on page 10, at line 6, with the following replacement heading:

-- BEST MODE FOR CARRYING OUT THE INVENTION DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS --

W0068787.1